Norges Bank Arcus Biosciences, Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $174,700 - $221,279	11,974 New	11,974 $182,000
Q4 2023 Feb 09, 2024	BUY	$13.43 - $19.63 $1.07 Million - $1.57 Million	79,824 New	79,824 $1.52 Million
Q3 2023 Nov 13, 2024	BUY	$17.62 - $23.54 $1.41 Million - $1.88 Million	79,824 New	79,824 $1.43 Million
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $2.71 Million - $3.62 Million	-153,826 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$16.97 - $22.03 $1.15 Million - $1.49 Million	67,850 Added 566.64%	79,824 $1.62 Million
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $2.35 Million - $3.05 Million	-138,305 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$15.96 - $23.15 $1.27 Million - $1.85 Million	79,824 New	79,824 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $626,972 - $1.14 Million	31,826 New	31,826 $658,000
Q3 2022 Nov 13, 2023	BUY	$23.23 - $30.07 $3.57 Million - $4.63 Million	153,826 New	153,826 $4.02 Million
Q2 2022 Aug 14, 2023	BUY	$17.23 - $37.73 $2.38 Million - $5.22 Million	138,305 New	138,305 $3.5 Million
Q3 2021 Nov 05, 2021	SELL	$26.93 - $37.68 $538,600 - $753,600	-20,000 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$22.75 - $35.77 $455,000 - $715,400	20,000 New	20,000 $549,000
Q2 2021 Aug 10, 2021	SELL	$22.75 - $35.77 $455,000 - $715,400	-20,000 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$26.16 - $41.39 $523,200 - $827,800	20,000 New	20,000 $562,000
Q1 2021 May 07, 2021	SELL	$26.16 - $41.39 $523,200 - $827,800	-20,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$17.0 - $32.36 $340,000 - $647,200	20,000 New	20,000 $519,000
Q4 2020 Feb 10, 2021	SELL	$17.0 - $32.36 $340,000 - $647,200	-20,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$17.14 - $25.47 $342,800 - $509,400	20,000 New	20,000 $343,000
Q2 2018 Jul 23, 2018	SELL	$12.24 - $17.05 $367,200 - $511,500	-30,000 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$15.44 - $17.71 $463,200 - $531,300	30,000 New	30,000 $463,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$139 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$77.7 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$49.4 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$42.8 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$34.6 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account